Replies to post #25398 on Therapeutic Solutions International Inc (TSOI)

[ADVFN_curncman]

Rao, Top NEWS today that completes the roadmap to getting NEUTRACEUTICAL/BIOLOGIC DRUG/PHARMA DRUG to the COVID-19 patients at warp speed. American innovation at the best and soon to be known to all the clinics over USA when the PEER JOURNAL REVIEW comes out soon!

TSOI is the only biotech offering THREE off-the-shelf ready product options (in the form of QUADRAMUNE, CELL THERAPY and STEMVACS2 to all COVID-19 patients encompassing the treatment pathways for all the pre and post effects of COVID-19 pandemic disease.

With Shelf offering completed this week, TSOI will have much needed funds to expand their sales and marketing to all the COVID-19/CANCER clinics all over USA through their WHOLESALE B2C ecommerce websites and digital social marketing to reach average joe/mary in the retail market all over the world.

Also, expecting some critical updates i guess next week about the amended INDs to be included in the 500 person clinical COVID-19 trial .

All of the above make TSOI an attractive and explosive OTC biotech investment in my humble and honest opinion.